Clinical Trial Update: CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CVM-1118 in combination with nivolumab for unresectable advanced hepatocellular carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• CVM-1118
• nivolumab (nivolumab)

Snippet

Sponsor: TaiRx, Inc. | Conditions: Hepatocellular Carcinoma, Advanced Cancer | Phase 2 | Status: RECRUITING